ATAI Life Sciences

IntelGenx Technologies Corp is an oral drug-delivery company that develops and manufactures pharmaceutical oral films using its VersaFilm technology. It focuses on novel immediate-release and controlled-release film products for the pharmaceutical market, including RIZAPORT, an oral film formulation of rizatriptan for acute migraine, and a pipeline of additional film-based candidates across CNS, pain, addiction, and oncology-supportive areas. The company provides end-to-end services to partners, covering research and development, analytical method development, clinical monitoring, regulatory support, IP, tech transfer, and manufacturing scale-up from lab to pilot and commercial production. It operates through collaborations and licensing arrangements with multiple pharma companies, including RedHill Biopharma, Par Pharmaceutical, Endo Ventures, Tilray, Gensco Pharma, Insud Pharma, and Cynapsus Therapeutics. IntelGenx serves Europe, Canada, and the United States and is headquartered in Montreal, Canada.

IntelGenx Technologies Corp is an oral drug-delivery company that develops and manufactures pharmaceutical oral films using its VersaFilm technology. It focuses on novel immediate-release and controlled-release film products for the pharmaceutical market, including RIZAPORT, an oral film formulation of rizatriptan for acute migraine, and a pipeline of additional film-based candidates across CNS, pain, addiction, and oncology-supportive areas. The company provides end-to-end services to partners, covering research and development, analytical method development, clinical monitoring, regulatory support, IP, tech transfer, and manufacturing scale-up from lab to pilot and commercial production. It operates through collaborations and licensing arrangements with multiple pharma companies, including RedHill Biopharma, Par Pharmaceutical, Endo Ventures, Tilray, Gensco Pharma, Insud Pharma, and Cynapsus Therapeutics. IntelGenx serves Europe, Canada, and the United States and is headquartered in Montreal, Canada.

IntelGenx Technologies Corp is an oral drug-delivery company that develops and manufactures pharmaceutical oral films using its VersaFilm technology. It focuses on novel immediate-release and controlled-release film products for the pharmaceutical market, including RIZAPORT, an oral film formulation of rizatriptan for acute migraine, and a pipeline of additional film-based candidates across CNS, pain, addiction, and oncology-supportive areas. The company provides end-to-end services to partners, covering research and development, analytical method development, clinical monitoring, regulatory support, IP, tech transfer, and manufacturing scale-up from lab to pilot and commercial production. It operates through collaborations and licensing arrangements with multiple pharma companies, including RedHill Biopharma, Par Pharmaceutical, Endo Ventures, Tilray, Gensco Pharma, Insud Pharma, and Cynapsus Therapeutics. IntelGenx serves Europe, Canada, and the United States and is headquartered in Montreal, Canada.

IntelGenx Technologies Corp is an oral drug-delivery company that develops and manufactures pharmaceutical oral films using its VersaFilm technology. It focuses on novel immediate-release and controlled-release film products for the pharmaceutical market, including RIZAPORT, an oral film formulation of rizatriptan for acute migraine, and a pipeline of additional film-based candidates across CNS, pain, addiction, and oncology-supportive areas. The company provides end-to-end services to partners, covering research and development, analytical method development, clinical monitoring, regulatory support, IP, tech transfer, and manufacturing scale-up from lab to pilot and commercial production. It operates through collaborations and licensing arrangements with multiple pharma companies, including RedHill Biopharma, Par Pharmaceutical, Endo Ventures, Tilray, Gensco Pharma, Insud Pharma, and Cynapsus Therapeutics. IntelGenx serves Europe, Canada, and the United States and is headquartered in Montreal, Canada.

IntelGenx Technologies Corp is an oral drug-delivery company that develops and manufactures pharmaceutical oral films using its VersaFilm technology. It focuses on novel immediate-release and controlled-release film products for the pharmaceutical market, including RIZAPORT, an oral film formulation of rizatriptan for acute migraine, and a pipeline of additional film-based candidates across CNS, pain, addiction, and oncology-supportive areas. The company provides end-to-end services to partners, covering research and development, analytical method development, clinical monitoring, regulatory support, IP, tech transfer, and manufacturing scale-up from lab to pilot and commercial production. It operates through collaborations and licensing arrangements with multiple pharma companies, including RedHill Biopharma, Par Pharmaceutical, Endo Ventures, Tilray, Gensco Pharma, Insud Pharma, and Cynapsus Therapeutics. IntelGenx serves Europe, Canada, and the United States and is headquartered in Montreal, Canada.

IntelGenx Technologies Corp is an oral drug-delivery company that develops and manufactures pharmaceutical oral films using its VersaFilm technology. It focuses on novel immediate-release and controlled-release film products for the pharmaceutical market, including RIZAPORT, an oral film formulation of rizatriptan for acute migraine, and a pipeline of additional film-based candidates across CNS, pain, addiction, and oncology-supportive areas. The company provides end-to-end services to partners, covering research and development, analytical method development, clinical monitoring, regulatory support, IP, tech transfer, and manufacturing scale-up from lab to pilot and commercial production. It operates through collaborations and licensing arrangements with multiple pharma companies, including RedHill Biopharma, Par Pharmaceutical, Endo Ventures, Tilray, Gensco Pharma, Insud Pharma, and Cynapsus Therapeutics. IntelGenx serves Europe, Canada, and the United States and is headquartered in Montreal, Canada.